Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)
China · Delayed Price · Currency is CNY 21.96
-0.19 (-0.86%)
Jun 10, 2026, 4:00 PM EDT
SHA:603207 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 541.32 | 524.7 | 474.23 | 471.56 | 456.46 | 401.29 |
Other Revenue | 0.59 | 0.59 | 0.36 | 0.31 | 0.43 | 0.48 |
| 541.9 | 525.28 | 474.58 | 471.87 | 456.89 | 401.77 | |
Revenue Growth (YoY) | 13.19% | 10.68% | 0.57% | 3.28% | 13.72% | 11.22% |
Cost of Revenue | 196.35 | 184.03 | 163.28 | 163.07 | 187.44 | 147.34 |
Gross Profit | 345.56 | 341.25 | 311.3 | 308.8 | 269.45 | 254.43 |
Selling, General & Admin | 85.43 | 78.17 | 60.57 | 59.47 | 54.65 | 95.06 |
Research & Development | 18.69 | 19.3 | 15.11 | 16.28 | 13.58 | 14.2 |
Other Operating Expenses | 3.95 | 3.73 | 1.91 | 2.4 | 4 | 3.01 |
Operating Expenses | 110.2 | 103.05 | 77.81 | 78.33 | 73.6 | 111.59 |
Operating Income | 235.35 | 238.19 | 233.49 | 230.48 | 195.85 | 142.84 |
Interest Expense | -0.03 | -0.03 | -0.03 | -0.05 | -0.07 | -0.09 |
Interest & Investment Income | 1.6 | 3.18 | 6.07 | 3.76 | 3.81 | 3.12 |
Other Non Operating Income (Expenses) | 0.03 | -0.08 | -0.03 | -0.05 | -0.04 | -0.01 |
EBT Excluding Unusual Items | 236.95 | 241.27 | 239.5 | 234.14 | 199.55 | 145.85 |
Gain (Loss) on Sale of Investments | - | - | - | 0.06 | 0.01 | 0.05 |
Gain (Loss) on Sale of Assets | 0.1 | 0.11 | - | - | 0 | - |
Asset Writedown | 0.07 | - | - | - | - | -0.01 |
Other Unusual Items | -0.65 | -0.52 | 0.01 | 2.97 | 6.49 | 8.66 |
Pretax Income | 236.85 | 241.23 | 239.51 | 237.17 | 206.06 | 154.55 |
Income Tax Expense | 33.19 | 33.74 | 34.24 | 33.54 | 30.88 | 28.28 |
Net Income | 203.65 | 207.49 | 205.27 | 203.63 | 175.18 | 126.27 |
Net Income to Common | 203.65 | 207.49 | 205.27 | 203.63 | 175.18 | 126.27 |
Net Income Growth | -4.35% | 1.08% | 0.81% | 16.24% | 38.74% | -21.05% |
Shares Outstanding (Basic) | 160 | 161 | 134 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 160 | 161 | 134 | 120 | 120 | 120 |
Shares Change (YoY) | 10.68% | 19.89% | 12.01% | -0.17% | -0.22% | - |
EPS (Basic) | 1.27 | 1.29 | 1.53 | 1.70 | 1.46 | 1.05 |
EPS (Diluted) | 1.27 | 1.29 | 1.53 | 1.70 | 1.46 | 1.05 |
EPS Growth | -13.58% | -15.69% | -10.00% | 16.44% | 39.05% | - |
Free Cash Flow | 70.62 | 106.56 | 128.27 | 120.11 | 75.61 | 167.03 |
Free Cash Flow Per Share | 0.44 | 0.66 | 0.96 | 1.00 | 0.63 | 1.39 |
Dividend Per Share | 1.070 | 1.070 | 1.500 | - | - | - |
Dividend Growth | -28.67% | -28.67% | - | - | - | - |
Gross Margin | 63.77% | 64.96% | 65.59% | 65.44% | 58.97% | 63.33% |
Operating Margin | 43.43% | 45.35% | 49.20% | 48.84% | 42.86% | 35.55% |
Profit Margin | 37.58% | 39.50% | 43.25% | 43.15% | 38.34% | 31.43% |
Free Cash Flow Margin | 13.03% | 20.29% | 27.03% | 25.45% | 16.55% | 41.57% |
EBITDA | 237.16 | 240.12 | 235.9 | 233.3 | 199.08 | 146.45 |
EBITDA Margin | 43.77% | 45.71% | 49.71% | 49.44% | 43.57% | 36.45% |
D&A For EBITDA | 1.81 | 1.93 | 2.41 | 2.83 | 3.24 | 3.61 |
EBIT | 235.35 | 238.19 | 233.49 | 230.48 | 195.85 | 142.84 |
EBIT Margin | 43.43% | 45.35% | 49.20% | 48.84% | 42.86% | 35.55% |
Effective Tax Rate | 14.02% | 13.99% | 14.29% | 14.14% | 14.99% | 18.30% |
Revenue as Reported | 541.9 | 525.28 | 474.58 | 471.87 | - | - |